BG
CRSP icon

Bellevue Group’s CRISPR Therapeutics CRSP Stock Holding History

Bellevue Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$239K Buy
5,016
+3,136
+167% +$165K 0.01% 131
2025
Q4 		$98.6K Buy
+1,880
New +$113K ﹤0.01% 163
2024
Q4 		– Sell
-610,000
Closed -$28.7M – 163
2024
Q3 		$28.7M Sell
610,000
-7,649
-1% -$388K 0.46% 63
2024
Q2 		$33.4M Sell
617,649
-2,301
-0.4% -$133K 0.54% 53
2024
Q1 		$42.3M Sell
619,950
-280,450
-31% -$20.1M 0.64% 49
2023
Q4 		$56.4M Buy
900,400
+2,000
+0.2% +$111K 0.86% 34
2023
Q3 		$40.8M Sell
898,400
-900
-0.1% -$46.5K 0.66% 47
2023
Q2 		$50.5M Sell
899,300
-500
-0.1% -$28.4K 0.72% 45
2023
Q1 		$40.7M Sell
899,800
-11,905
-1% -$578K 0.59% 53
2022
Q4 		$37.1M Sell
911,705
-16,600
-2% -$881K 0.49% 61
2022
Q3 		$60.7M Buy
928,305
+6,300
+0.7% +$457K 0.87% 39
2022
Q2 		$56M Sell
922,005
-4,900
-0.5% -$288K 0.79% 41
2022
Q1 		$58.2M Sell
926,905
-47,779
-5% -$3M 0.68% 52
2021
Q4 		$73.9M Hold
974,684
– – 0.76% 45
2021
Q3 		$109M Buy
974,684
+7,800
+0.8% +$980K 1.11% 28
2021
Q2 		$157M Sell
966,884
-11,500
-1% -$1.4M 1.53% 16
2021
Q1 		$119M Buy
978,384
+68,700
+8% +$10.4M 1.26% 24
2020
Q4 		$139M Sell
909,684
-39,578
-4% -$4.68M 1.6% 15
2020
Q3 		$79.4M Buy
949,262
+148,800
+19% +$13.2M 1.1% 27
2020
Q2 		$58.8M Hold
800,462
– – 0.83% 35
2020
Q1 		$33.9M Buy
800,462
+70,000
+10% +$3.61M 0.66% 43
2019
Q4 		$44.5M Sell
730,462
-106,700
-13% -$5.83M 0.71% 41
2019
Q3 		$34.3M Buy
837,162
+26,700
+3% +$1.28M 0.64% 42
2019
Q2 		$38.2M Buy
+810,462
New +$32.4M 0.65% 40

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group's CRSP Position: Q1 2026 in Review

Bellevue Group increased its CRISPR Therapeutics (CRSP) stake by 167% in Q1 2026, buying an estimated $165K and bringing the position to 5,016 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #131.

Bellevue Group first reported a position in CRSP in Q2 2019 and has held it in 24 quarters since. The position peaked at $157M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Bellevue Group held 5,016 shares of CRISPR Therapeutics worth $239K as of Q1 2026.
  • Bellevue Group bought 3,136 CRISPR Therapeutics shares in Q1 2026, an estimated $165K.
  • CRISPR Therapeutics made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #131 holding.
  • Bellevue Group first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • Bellevue Group's CRISPR Therapeutics position peaked at $157M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.